Fontanari D, Perulli L, Conte F, Tambato E, Toso V, Zanetti R
Cephalalgia. 1983 Aug;3 Suppl 1:189-91. doi: 10.1177/03331024830030S133.
The antimigraine efficacy of dihydroergotamine methanesulphonate in the pharmaceutical form of planned release capsules has been evaluated. Forty-nine subjects were treated, 39 suffering from common migraine 10 from tension vascular headache, for a period of 90 days, with an oral dose of 15 mg twice daily. The product was found to be efficacious in 71% of the common migraine cases, while unsatisfactory or nil results were obtained in the remaining 29%. In the tension-vascular headache cases, efficacy was 40% compared to 60% unsatisfactory or nil results. Tolerance was good in 43 cases, while transient digestive disorders (nausea and vomiting) occurred in 6; in 2 cases the treatment had to be withdrawn for allergic erythema. The results demonstrate that the drug is indicated in cases of common migraine, while it does not appear to significantly influence the course of attacks of tension-vascular headache.
已对甲磺酸二氢麦角胺缓释胶囊剂型的抗偏头痛疗效进行了评估。49名受试者接受了治疗，其中39名患有普通偏头痛，10名患有紧张性血管性头痛，为期90天，口服剂量为每日两次，每次15毫克。该产品在71%的普通偏头痛病例中被发现有效，而其余29%的病例效果不令人满意或无效。在紧张性血管性头痛病例中，有效率为40%，相比之下，60%的病例效果不令人满意或无效。43例耐受性良好，6例出现短暂的消化系统紊乱（恶心和呕吐）；2例因过敏性红斑而不得不停止治疗。结果表明，该药物适用于普通偏头痛病例，而似乎对紧张性血管性头痛发作的病程没有显著影响。
